Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | NPC1 | O15118 | 2/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.73 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.71 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.70 |
| ▸ | PTAFR | P25105 | 3/20 | 0.70 |
| ▸ | NAMPT | P43490 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30969954 | 0.91 | RAB9A (1.00) | RAB9AKMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL2129716 | 0.91 | RAB9A (1.00) | RAB9AKMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL8739011 | 0.88 | RAB9A (0.66) | RAB9AKMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL14797299 | 0.87 | HDAC2 (0.64) | RAB9AKMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL13211915 | 0.87 | RAB9A (0.70) | RAB9AKMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL506616 | 0.86 | NAMPT (0.67) | RAB9AKMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL13766380 | 0.86 | HDAC2 (0.63) | RAB9AKMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL5214944 | 0.85 | RAB9A (0.70) | RAB9AKMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL13762095 | 0.85 | ALDH1A1 (0.76) | RAB9AKMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL1831475 | 0.85 | HDAC2 (0.62) | RAB9AKMT2AMEN1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633347-A1 | 2-PYRROLIDONE DERIVATIVES AND USE THEREOF AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-03-15 | — | — | EP | claimed |
| WO-2004110434-A1 | 2-PYRROLIDONE DERIVATIVES AND USE THEREOF AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | claimed |
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2025-02-06 | — | — | US | disclosed |
| CN-101501035-B | Pyrimidine derivatives as PI3K inhibitors and uses thereof | CHUGAI PHARMACEUTICAL CO LTD | 2013-01-23 | — | — | CN | disclosed |
| CN-1968929-B | Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicaments | SANOFI AVENTIS DEUTSCHLAND | 2010-09-08 | — | — | CN | disclosed |
| CN-101501035-A | Pyrimidine derivatives as P13K inhibitors and uses thereof | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| US-20080033020-A1 | 3-Pyridinylethylbenzamide Derivatives as Fungicides | BAYER CROPSCIENCE S.A. (FR) | 2008-02-07 | — | — | US | disclosed |
| US-20080033020-A1 | 3-Pyridinylethylbenzamide Derivatives as Fungicides | BAYER CROPSCIENCE S.A. (FR) | 2008-02-07 | — | — | US | disclosed |
| US-20070249690-A1 | N-[2-(4-Pyridinyl)Ethyl]Benzamide Derivatives as Fungicides | BAYER CROPSCIENCE S.A. (FR) | 2007-10-25 | — | — | US | disclosed |
| CN-1968929-A | Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-05-23 | — | — | CN | disclosed |
| EP-1773777-A1 | N-[2-(4-PYRIDINYL)ETHYL]BENZAMIDE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE SA (FR) | 2007-04-18 | — | — | EP | disclosed |
| EP-1773776-A1 | 3-PYRIDINYLETHYLBENZAMIDE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE SA (FR) | 2007-04-18 | — | — | EP | disclosed |
| EP-1633347-A1 | 2-PYRROLIDONE DERIVATIVES AND USE THEREOF AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-03-15 | — | — | EP | disclosed |
| WO-2006011719-A1 | N-SUBSTITUTED-SULFAMOYLBENZOIC ACID DERIVATIVES, METHOD FOR PREPARING THEREOF AND ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | B & C BIOPHARM CO., LTD. (KR) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006008192-A1 | N-[2-(4-PYRIDINYL)ETHYL]BENZAMIDE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE SA (FR) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006008191-A1 | 3-PYRIDINYLETHYLBENZAMIDE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE SA (FR) | 2006-01-26 | — | — | WO | disclosed |
| WO-2004110434-A1 | 2-PYRROLIDONE DERIVATIVES AND USE THEREOF AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | WNT1, XPOT, CTNNBL1 | RAB9A 3071/4885KMT2A 598/4885MEN1 1646/4885 |
| US-20080033020-A1 | 3-Pyridinylethylbenzamide Derivatives as Fungicides | CYP1A2, CYP4B1, CYP4F2 | RAB9A 1490/4885KMT2A 1949/4885MEN1 753/4885 |
| US-20070249690-A1 | N-[2-(4-Pyridinyl)Ethyl]Benzamide Derivatives as Fungicides | CYP1A2, CYP3A5, CYP4B1 | RAB9A 1089/4885KMT2A 1470/4885MEN1 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.